Nafarelin in the management of endometriosis: quality of life assessment.

Abstract

Quality of life is important when comparing the relative advantages of nafarelin versus danazol for the treatment of endometriosis. Recent studies have investigated the potential differences between the safety profiles of nafarelin and danazol and the impact of these profiles on the patient's quality of life. Results show that although these drugs have similar efficacy, they are associated with very different safety profiles. Most notable are the androgenic effects such as weight gain associated with danazol. With nafarelin, hypoestrogenic side effects, such as hot flashes, are more common. More important, these differences in safety profiles may prove to be relevant to patient satisfaction and compliance with therapy.

• Authors: K A Burry
• Journal: American journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 166 Issue 2 Pg. 735-9 (Feb 1992) ISSN: 0002-9378 [Print] United States
• PMID: 1531576 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Estrogens
• Nafarelin
• Gonadotropin-Releasing Hormone
• Danazol

Topics

• Climacteric (drug effects)
• Danazol (adverse effects, therapeutic use)
• Endometriosis (drug therapy, metabolism, rehabilitation)
• Estrogens (deficiency)
• Female
• Gonadotropin-Releasing Hormone (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Nafarelin
• Quality of Life
• Sex